Trost Allylic Alkylation

Trost Asymmetric Allylic Alkylation
Dowpharma^SM has licensed worldwide from Stanford University for the Trost palladium- and molybdenum-based catalysts for asymmetric allylic alkylation reactions. These carbon-heteroatom and carbon-carbon bond-forming technologies allow the construction of complex structural features. We have developed the synthesis of the ligands and they are now availble for large-scale commercial applications.

Asymmetric allylic alkylation is truly an enabling methodology, allowing a plethora of chiral molecules to be synthesized. Dowpharma has developed many processes to useful synthetic intermediates utilizing the Trost technology. This includes routes to vinylglycinol, 2-aminotetralins, 3-buten-1,2-diol, Calanolide A, 2-cyclohexenylamine and quaternary amino acids.

For more information:
Trost Molybdenum Technology license from Stanford Univ. (244KB PDF)
Trost Palladium Technology license from Stanford Univ. (227KB PDF)
Application of Trost palladium catalyzed asymmetric allylic alkylation technology (311KB PDF)

In order to view some information you may need to download Adobe Reader.

^SMService mark of The Dow Chemical Company


Capabilities and Services Biocatalysis Biocatalysis Capability Collaborators Enzyme Classes Chemocatalysis Asymmetric Hydrogenation Hydroformylation Trost Allylic Alkylation Complex Synthesis Products Offered Process Development Customer Needs Development Timeline Emerging Pharma Catalyst/Ligand Availability Unnatural Fmoc Amino Acids Unnatural Boc Amino Acids 2-Alkyl Succinates Amines Alcohols Functionalized Cyclopentanes Scaffolds Facilities Literature and Resources Asymmetric Hydrogenation Dowpharma Scientific Publications Hydroformylation Trost Allylic Alkylation Complex Synthesis Biocatalysis Process Development General Publications News Center Source: Aquapharm Bio-Discovery Ltd Enters a Collaboration Deal with Dowpharma<sup>SM</sup> Contract Manufacturing Services. Dowpharma Relaunches Web Site, Will Make Donation to UNICEF Dow Expands Presence in Pharmaceutical Market, Uniting Existing Offers Under Dowpharma Portfolio Dowpharma Announces New Capabilities in Asymmetric Hydroformylation for Pharmaceutical Applications License of JST Catalyst Technology Expands Dowpharma’s Chiral Commercial Production Capabilities Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan Events Calendar Contact Us	Trost Allylic Alkylation Trost Asymmetric Allylic Alkylation Dowpharma^SM has licensed worldwide from Stanford University for the Trost palladium- and molybdenum-based catalysts for asymmetric allylic alkylation reactions. These carbon-heteroatom and carbon-carbon bond-forming technologies allow the construction of complex structural features. We have developed the synthesis of the ligands and they are now availble for large-scale commercial applications. Asymmetric allylic alkylation is truly an enabling methodology, allowing a plethora of chiral molecules to be synthesized. Dowpharma has developed many processes to useful synthetic intermediates utilizing the Trost technology. This includes routes to vinylglycinol, 2-aminotetralins, 3-buten-1,2-diol, Calanolide A, 2-cyclohexenylamine and quaternary amino acids. For more information: Trost Molybdenum Technology license from Stanford Univ. (244KB PDF) Trost Palladium Technology license from Stanford Univ. (227KB PDF) Application of Trost palladium catalyzed asymmetric allylic alkylation technology (311KB PDF) In order to view some information you may need to download Adobe Reader. ^SMService mark of The Dow Chemical Company
	Small Molecules Dow Home Privacy Statement Internet Disclaimer Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2008). All Rights Reserved.